New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Some light is shed on Dreamm-7, but precisely why this trial was successful remains a mystery.
Pelabresib's partial win at ASH was enough to persuade Novartis to pull the acquisition trigger.
Early-stage assets missing from the group’s pipeline include several ADCs, as the acquisition of ImmunoGen looms.
On a wing and a prayer AbbVie takes livmoniplimab into phase 3.
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.